EnVVeno Medical Corporation (NASDAQ:NVNO) | WebDisclosure

Switch to English

10238	Sociétés
211363	Mots-clés
141296	Articles
111973	Communiqués

Accueil
Sociétés
EnVVeno Medical Corporation

COMMUNIQUÉ DE PRESSE

publié le 16/04/2024 à 15:00, il y a 2 années

New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
enVVeno Medical Corporation to present additional topline efficacy data from VenoValve U.S. pivotal trial at 2024 Charing Cross International Symposium in London. Data to review clinical status of severe Chronic Venous Insufficiency patients post VenoValve implantation

VenoValve Chronic Venous Insufficiency EnVVeno Medical Corporation SAVVE Trial Charing Cross International Symposium
BRÈVE

publiée le 09/04/2024 à 14:50, il y a 2 années

EnVVeno Medical Appoints Andrew Cormack as Chief Commercial Officer to Spearhead VenoValve® Commercialization

EnVVeno Medical VenoValve® Chronic Venous Insufficiency (CVI) SAVVE U.S. Pivotal Study Commercialization Strategy
BRÈVE

publiée le 09/04/2024 à 14:50, il y a 2 années

EnVVeno Medical nomme Andrew Cormack au poste de directeur commercial pour diriger la commercialisation de VenoValve®

EnVVeno Medical VenoValve® Insuffisance Veineuse Chronique (IVC) Étude Pivot Américaine SAVVE Stratégie De Commercialisation
COMMUNIQUÉ DE PRESSE

publié le 09/04/2024 à 14:45, il y a 2 années

enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer
enVVeno Medical Corporation appoints Andrew Cormack as Chief Commercial Officer to drive VenoValve's commercialization strategy. PMA application for FDA approval on track for Q4 2024

FDA Approval VenoValve EnVVeno Medical Corporation Commercialization Strategy Andrew Cormack
BRÈVE

publiée le 15/03/2024 à 14:05, il y a 2 années 1 mois

EnVVeno Medical to Showcase Its Innovations in an Upcoming Virtual Investor Event

EnVVeno Medical Medical Innovation Virtual Investor Event Venous Disease Treatment Corporate Overview
BRÈVE

publiée le 15/03/2024 à 14:05, il y a 2 années 1 mois

EnVVeno Medical présentera ses innovations lors d'un prochain événement virtuel pour les investisseurs

Innovation Médicale EnVVeno Medical Événement Virtuel Pour Les Investisseurs Traitement Des Maladies Veineuses Vue D'ensemble De L'entreprise
COMMUNIQUÉ DE PRESSE

publié le 15/03/2024 à 14:00, il y a 2 années 1 mois

enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity
enVVeno Medical to present at Virtual Investor Lunch Break on March 21, 2024, with CEO Robert Berman discussing the company's outlook and the enVVeno Opportunity

EnVVeno Medical Venous Disease Treatment Virtual Investor Lunch Break Robert Berman Bioprosthetic Solutions
BRÈVE

publiée le 06/03/2024 à 14:45, il y a 2 années 1 mois

EnVVeno Medical Corporation Announces Positive Results from VenoValve Pivotal Trial

FDA Approval EnVVeno Medical VenoValve Chronic Venous Insufficiency Clinical Improvement
BRÈVE

publiée le 06/03/2024 à 14:45, il y a 2 années 1 mois

EnVVeno Medical Corporation annonce les résultats positifs de l'essai pivot VenoValve

EnVVeno Medical Insuffisance Veineuse Chronique VenoValve Approbation De La FDA Amélioration Clinique
COMMUNIQUÉ DE PRESSE

publié le 06/03/2024 à 14:40, il y a 2 années 1 mois

Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
enVVeno Medical presents positive topline efficacy data from the SAVVE U.S. pivotal trial for the VenoValve at the 2024 American Venous Forum Annual Meeting, showing significant clinical improvement in CVI patients

EnVVeno Medical VenoValve Clinical Improvement SAVVE Trial CVI Patients

Les Echos

Publié le 17/04/2026 à 20:30, il y a 1 jour 13 heures

ALTAREA - Déclaration d’opérations sur actions propres
Publié le 17/04/2026 à 19:00, il y a 1 jour 15 heures

Cegedim : Publication du Document d’Enregistrement Universel 2025
Publié le 17/04/2026 à 19:00, il y a 1 jour 15 heures

Cegedim: Release of its 2025 Universal Registration Document
Publié le 17/04/2026 à 17:45, il y a 1 jour 16 heures

Carrefour announces the sale of its minority stake in CarrefourSA in Turkey to Aydın
Publié le 17/04/2026 à 17:45, il y a 1 jour 16 heures

Carrefour annonce la cession de sa participation minoritaire dans CarrefourSA en Turquie à Aydın

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 18/04/2026 à 04:00, il y a 1 jour 6 heures

Formation Metals Responds to OTC Markets Request on Recent Promotional Activity
Publié le 18/04/2026 à 02:00, il y a 1 jour 8 heures

AI/ML Innovations Announces Completion of Share Issuance
Publié le 18/04/2026 à 01:35, il y a 1 jour 8 heures

Medicure Announces Resignation of President and Chief Operating Officer
Publié le 18/04/2026 à 01:00, il y a 1 jour 9 heures

Onco-Innovations Strengthens Executive Leadership with Appointment of Dr. Islam Mohamed as Chief Medical Officer and Stephen M. Novak as Chief of Research and Development
Publié le 18/04/2026 à 00:00, il y a 1 jour 10 heures

Redwood AI Announces Collaboration with Aidos Innovations, Aimed at Enhancing Public Safety Collaboration with B.C. Government, Canadian Federal and Local Law Enforcement Agencies to Tackle the Fentanyl Crisis in British Columbia

Voir tout ACCESSWIRE

EQS Group

Publié le 18/04/2026 à 00:05, il y a 1 jour 10 heures

ESCMID Global: Maternal RSV vaccination cuts infant hospitalisation risk by over 80%, major UKHSA study finds
Publié le 17/04/2026 à 21:39, il y a 1 jour 12 heures

Linedata Services: Mise à disposition du Document d’Enregistrement Universel 2025 incluant le Rapport Financier Annuel 2025
Publié le 17/04/2026 à 20:33, il y a 1 jour 13 heures

LLB General Meeting 2026 – Shareholders approve all proposals of the Board of Directors
Publié le 17/04/2026 à 19:35, il y a 1 jour 14 heures

Stabilisation Notice
Publié le 17/04/2026 à 19:30, il y a 1 jour 14 heures

KAP AG: REFINANCING CONCEPT AGREED; NEW SYNDICATED LOAN SECURES FLEXIBILITY FOR THE ONGOING TRANSFORMATION PROCESS